Last updated: April 25, 2026
Who Supplies Dabigatran Etexilate Mesylate (API and Finished Dosage Forms)?
Dabigatran etexilate mesylate is a branded anticoagulant active. Supply chains bifurcate into (1) API manufacture (dabigatran etexilate, commonly in salt form such as mesylate) and (2) finished-dose tablets for markets where brand and generics are marketed.
1) What are the core global suppliers for the API (dabigatran etexilate mesylate)?
The most reliable way to map API suppliers is to tie them to regulatory submissions and manufacturing authorizations (US FDA, EMA, and major dossier jurisdictions). Across public regulatory records, the following entities are repeatedly associated with dabigatran etexilate manufacturing and supply for branded and generic use.
API and salt-form manufacturing (commonly referenced across dossiers)
| Supplier / Manufacturer |
Typical role in supply chain |
Evidence anchor (regulatory linkage) |
| Boehringer Ingelheim |
Originator API manufacturing and commercial supply |
Brand ownership and dossier references for dabigatran etexilate products in major markets (originator filings, EMA/US product documentation) |
| Par Pharmaceutical (through contract manufacturing network) |
API and/or intermediate sourcing into generic tablets |
Generic product approvals reference CMOs/packagers and manufacturing sites; Par product dossiers commonly list manufacturing participants |
| Nippon Shinyaku / local partners (Japan supply chain) |
API and intermediates for market feed |
Japan market manufacturing participation for dabigatran etexilate products in public product records |
| Generic manufacturers’ contracted API/CMO networks (Europe/India/US) |
Contract API sourcing and final tablet manufacture |
Multiple ANDA/EMA generic authorizations list manufacturing sites and block-and-release partners |
2) Who supplies finished dabigatran etexilate mesylate tablets (marketed products)?
Finished-dose supply is easier to enumerate at the label level because each approved product has listed manufacturers for drug product release and packaging.
Finished-dose tablet supply participants (by branded/generic label)
| Market / Product type |
Example label |
Supplier(s) typically listed for drug product manufacturing/release |
| Branded (originator) |
Pradaxa (dabigatran etexilate mesylate) |
Boehringer Ingelheim drug product manufacturing sites listed on approved labeling (US and EU) |
| US generics (ANDA) |
Generic dabigatran etexilate mesylate capsules/tablets depending on label |
Each ANDA lists drug product manufacturer(s) and packager(s) involved in release |
| EU generics (national + centralized variations) |
Generic dabigatran etexilate products |
EMA-linked and national product authorizations list manufacturing sites and QP release sites |
What supplier constraints matter for dabigatran etexilate mesylate?
How do firms manage stability, salt form, and GMP release across the chain?
Dabigatran etexilate products rely on tightly controlled synthesis and salt handling because:
- The drug substance is supplied as a salt form (commonly mesylate) to meet physical and stability needs aligned with the reference product.
- Finished-dose supply depends on packaging and humidity control because oral anticoagulants are sensitive to formulation and storage parameters.
What practical supplier selection signals show up in approved dossiers?
Across anticoagulant supply networks, approval-linked supplier lists typically include:
- API or drug substance manufacturer(s) (and in some submissions, intermediate sites)
- Drug product manufacturer(s) (tablet/capsule manufacturing)
- Packager(s) (bottling/blistering)
- Quality control and release sites (including QP release in EU)
Supplier shortlist for decision-making
If the goal is to map “who actually supplies” rather than “who owns the brand,” the decision-grade shortlist is:
- Originator supply chain node: Boehringer Ingelheim
- Generic market supply chain nodes: Drug product manufacturers and packagers named on approved generic labels tied to ANDA/EMA authorizations
- API/CMO network nodes: Contract manufacturers listed as drug substance and intermediate sites within those same approvals
That is the only repeatable structure that holds across jurisdictions because dabigatran etexilate is supplied via multi-tier outsourcing in most generic chains.
Key Takeaways
- Dabigatran etexilate mesylate supply splits into API/drug substance and finished-dose drug product networks.
- Boehringer Ingelheim is the originator node for branded commercial supply.
- Generic supply is executed by drug product manufacturers, packagers, and contract API/CMO networks named directly in regulatory approvals for each market product.
- The authoritative way to identify the active suppliers is to use approved-label manufacturing lists rather than relying on informal commercial supplier directories.
FAQs
1) Is dabigatran etexilate mesylate supplied only by the originator?
No. The originator supplies branded products, while generics supply finished-dose products through label-listed manufacturing and packaged release chains.
2) What is the most reliable method to identify actual dabigatran etexilate mesylate suppliers?
Use the manufacturing site lists on approved product labeling/dossier entries (ANDA/EMA and major national authorizations), which enumerate API/drug substance, drug product, and packager/release sites.
3) Who controls dabigatran etexilate mesylate specifications?
The specifications align with the reference product’s approved quality standard; supplier qualification is governed by GMP and regulatory release requirements in the dossier and local regulatory framework.
4) Do suppliers differ by market?
Yes. Even for the same active, tablet/capsule manufacturing sites and packaging partners often differ by country.
5) Are API and finished-dose suppliers always the same companies?
No. Many generic supply chains use separate entities for API/drug substance and drug product manufacturing under contract.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Pradaxa (dabigatran etexilate) labeling and product information. FDA.
[2] European Medicines Agency. (n.d.). Pradaxa product information and assessment documentation for dabigatran etexilate. EMA.
[3] DailyMed. (n.d.). Pradaxa (dabigatran etexilate mesylate) drug label. National Library of Medicine.
